Press Release

EV-Based Liquid Biopsy Market to Grow at 9.58% CAGR through 2029

An increase in funding from government and private institutions to eradicate cancer is expected to drive the Global EV-Based Liquid Biopsy Market growth in the forecast period, 2025-2029.


According to TechSci Research report, “EV-Based Liquid Biopsy Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”, the Global EV-Based Liquid Biopsy Market stood at USD 89.10 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 9.58% through 2029. The global EV-Based Liquid Biopsy market is expected to grow in the next few years due to several factors that shape its growth and trajectory. The urgent need for improved cancer diagnostics and treatment monitoring, and the advancements in technology and data analysis have significantly enhanced the sensitivity and specificity of EV-based liquid biopsy tests that drives the demand for EV-based liquid biopsy.

The growing investment and research in the field of oncology and liquid biopsy technology are also major drivers for the EV based liquid biopsy market. Pharmaceutical companies, diagnostic laboratories, and biotechnology firms are actively investing in the development of EV-based liquid biopsy products, leading to a competitive market landscape, and driving innovation in the field. This leads to a surge in the EV Based liquid biopsy market in the coming years.

Also, the rise in cancer incidence worldwide has created a substantial market opportunity for EV-based liquid biopsy. As cancer cases continue to rise, there is an increasing need for precise, non-invasive diagnostics such as liquid biopsy to help with early detection, patient follow-up, and disease management.

Many countries have launched national cancer research programs and funding initiatives to support research in oncology, which includes exploring novel diagnostic methods like liquid biopsies. These programs aim to promote the development of innovative technologies that can aid in early cancer detection, monitoring, and personalized treatment strategies. As liquid biopsy technologies, including EV-based approaches, gain traction in the scientific community, they could potentially receive support through these existing cancer research initiatives. Also, regulatory agencies in different countries play a vital role in shaping the environment for medical technologies, including liquid biopsy tests. They work to ensure the safety, efficacy, and quality of medical devices and diagnostics, which includes liquid biopsy assays. By providing clear guidelines and pathways for regulatory approval, governments can facilitate the adoption and commercialization of advanced liquid biopsy technologies, including those based on EVs. This results in boosting the EV-Based Liquid Biopsy market in the coming years.

However, there are several challenges faced by the EV-Based Liquid Biopsy market. One of the primary challenges is the technical complexities associated with isolating and characterizing EVs from biofluids. The process can be labor-intensive, prone to variability, and requires standardization to ensure consistent and reliable results. Another key challenge is the identification of specific and reliable biomarkers within EVs that can accurately indicate different cancer types and stages. The heterogeneity of EVs and the dynamic nature of cancer present complexities in pinpointing consistent and universally applicable biomarkers. Extensive research and validation efforts are needed to discover and validate reliable EV-based biomarkers that can be used effectively for cancer diagnosis and monitoring. Also, Proper sample handling and storage are critical challenges as well. EVs are sensitive to degradation and can be affected by improper collection, handling, and storage, leading to compromised data quality and inaccurate results. Maintaining standardized procedures for sample handling is essential to maintain the integrity of EVs and their cargo. Lastly, cost-effectiveness is a significant challenge for the widespread adoption of EV-based liquid biopsy. The development, validation, and commercialization of these tests can be expensive, and efforts to optimize production processes and reduce costs are needed to make the technology more accessible to a broader population. These challenges lead to a decline in the EV Based liquid biopsy market in the coming years.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global EV-Based Liquid Biopsy Market

The Global EV-Based Liquid Biopsy Market is segmented into offering, workflow, technology, sample type, end user, regional distribution, and company

Based on the sample type, global EV-Based Liquid Biopsy market is segmented into blood, urine, saliva, and others. The dominant sample type for EV-Based Liquid Biopsy is Blood. Blood is likely to be the dominant sample type in the EV-based liquid biopsy market. Blood offers a rich source of circulating EVs, and its ease of collection makes it a preferred choice for non-invasive cancer detection and monitoring, driving its dominance in the market. The blood-based liquid biopsies provide a holistic view of systemic health, allowing for the detection of cancer and other diseases at early stages, when treatment options are most effective. Additionally, blood samples are relatively stable and amenable to processing and storage, enabling convenient transportation and analysis in centralized laboratories.

Based on region, while other regions such as Europe and Asia Pacific are also witnessing rapid growth in the adoption of EV-based liquid biopsy technologies, North America remains at the forefront due to its robust research infrastructure, strong regulatory environment, and high demand for advanced diagnostic solutions. North America's large patient population, coupled with high healthcare expenditure, drives significant demand for advanced diagnostic technologies for cancer and other diseases. Liquid biopsy assays, including those based on extracellular vesicles (EVs), offer non-invasive and sensitive tools for early cancer detection, treatment monitoring, and personalized medicine, thereby gaining traction among healthcare providers and patients alike. Strategic collaborations between academia, industry, and government agencies facilitate the translation of research findings into clinically actionable liquid biopsy assays. These collaborations foster innovation, drive market growth, and contribute to North America's leadership position in the Global EV-Based Liquid Biopsy Market.


Major companies operating in Global EV-Based Liquid Biopsy Market are:

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd.
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation


Download Free Sample Report

Customers can also request for 10% free customization on this report


“North America was likely the dominant region for the EV-based liquid biopsy market. The region's dominance can be attributed to several factors, including a robust healthcare infrastructure, high investments in cancer research and precision medicine, and a strong presence of key players in the biotechnology and diagnostics industries. Additionally, North America has a large pool of patients and healthcare providers eager to adopt innovative diagnostic technologies, leading to early adoption and commercialization of EV-based liquid biopsy products. This results in boosting the EV-based liquid biopsy market in the coming years”, said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering (Kits & Assays, Services, Instruments), By Workflow (Sample Preparation, Sequencing, Data Analysis), By Technology (Isolation Technologies, Analysis Technologies), By Sample Type (Blood, Urine, Saliva, and Others), By End user (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Clinical Laboratories), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global EV-Based Liquid Biopsy Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global EV-Based Liquid Biopsy Market.



TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]


Relevant News